Flagship went global last year, opening new offices in London and Singapore as part of a concerted expansion of the venture creation firm’s startup ecosystem. But it may be a bit before the Asia-Pacific outpost spurs new partnerships in China, according to CEO Noubar Afeyan, Ph.D.
Flagship-founded Axcella Health is closing its doors, with stockholders approving the dissolution of the metabolic modulator biotech yesterday.
Flagship Pioneering — the platform company behind the likes of Moderna and Seres Therapeutics — launched a UK hub on Tuesday as part of its broader commitment to investing in the UK life science space.
New Flagship Pioneering biotech Quotient Therapeutics has lots to be thankful for this year, namely $50 million in cash, a new U.K. outpost to work from and a formal unveiling as the holiday season approaches.
Flagship Pioneering is staking out a new home base in Asia, recruiting a longtime McKinsey vet — and a colleague to Flagship CEO Noubar Afeyan — to start working on a fresh set of strategic deals in the region for its portfolio of biotechs. The move to tap André Andonian for the role of Singapore chair comes after a move into London earlier in the year underscored Flagship’s ambitions outside the US.
Laronde and Senda Biosciences, two biotech startups founded by Flagship Pioneering that collectively raised more than $750 million, are merging to form a new company called Sail Biomedicines, the life science investment group announced Thursday morning.
Flagship Pioneering, probably best known for funding Moderna, is revamping its brand to better define itself — and attract new talent, partners and investors.
The draw of Flagship Pioneering strikes again. After leaving his position as GSK’s head of R&D, John Lepore, M.D., is set to become a CEO-partner at Flagship and will helm the portfolio company’s ProFound Therapeutics.
John Lepore, the former right-hand man for Hal Barron and Tony Wood at GSK, is departing the UK pharma giant to lead a Flagship Pioneering startup, joining the growing list of industry veterans recruited by the biotech incubator.
CAMBRIDGE, Mass., Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer. In this role, she will be responsible for driving and supporting business development across the Flagship ecosystem, leading the effort to forge strong partnerships between Flagship companies and the biopharma industry. She will also work closely with the Pioneering Medicines unit of Flagship as we continue to invest in and grow our corporate alliance strategy.